Founded in 2012 as a spin-off from Chalmers University of Technology in Sweden, Fluicell is a public biotech company providing platforms to investigate cell behavior like never before. The company is a world leader and pioneer in open-volume microfluidics for the life sciences, and holds a strong IP and patent position with five different patent families in the estate.
The company has commercialized a product portfolio to study individual cells, primarily in the field of drug development and cell biology.
The BioPen® is the first single-cell lab-on-a-tip tool for the life sciences sector and is used by leading universities and national health laboratories globally. It is a unique drug delivery system for targeting individual cells in vitro without contaminating the surrounding environment.
The Dynaflow® Resolve system is considered by many to be the best secondary ion channel screening platform on the market. Launched in 2004, the Dynaflow platform is an established product with global big pharma and biotech companies as customers.
As a further development of Fluicell’s existing product portfolio, the company has developed a unique high-resolution 3D single-cell bioprinting technology under the name Biopixlar®. With this system, complex tissue-like structures can be created where positioning of individual cells can be controlled.